Skip to search formSkip to main contentSkip to account menu

SPP100

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

aliskiren

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Experimental and Clinical Pharmacology: Clinical implications of renin inhibitors
Direct renin inhibition lowers blood pressure by an effective blockade of the renin-angiotensin system 
Highly Cited
2007
Highly Cited
2007
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor…
Due to its function in the rate limiting initial step of the renin-angiotensin system, renin is a particularly promising target… 
2006
2006
Speedel staunches the renin cascade at its source.
2005
2005
Renin inhibition: new potential for an old therapeutic target.
Experimental and clinical studies have highlighted the importance of the local renin-angiotensin system (RAS) as a pathogenetic… 
Highly Cited
2002
Highly Cited
2002
Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril
Renin is the main determinant of angiotensin (Ang) II levels. It, therefore, always appeared desirable to reduce Ang II levels by… 
Highly Cited
2002
Highly Cited
2002
Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril.
2001
2001
O-36: The orally active renin inhibitor SPP100 blocks the renin-angiotensin system in humans equally well as enalapril*
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)